Trial Profile
Combined modality treatment for patients with stage IV melanoma: Cyclophosphamide and a dendritic cell vaccine loaded with killed allogeneic melanoma cells.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2014
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dendritic cell vaccine-SBI Biotech (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 24 May 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 17 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 16 Jul 2011 Actual initiation date (Jul 2011) added as reported by University Hospital Medical Information Network - Japan.